<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1039/d5nh00782h</dc:identifier><dc:language>eng</dc:language><dc:creator>Esteban-Pérez, Natalia</dc:creator><dc:creator>Del Sol-Fernández, Susel</dc:creator><dc:creator>Martín-Rapún, Rafael</dc:creator><dc:creator>Martínez de la Fuente, Jesús</dc:creator><dc:title>Controlled release of glucocorticoid via PLGA nanoparticles for modulating macrophage polarization in inflammation situations</dc:title><dc:identifier>ART-2026-148745</dc:identifier><dc:description>Glucocorticoids are among the most widely used anti-inflammatory and immunosuppressive drugs. However, their prolonged administration is associated with a wide range of adverse side effects including long-lasting immunosuppression. In this study, we aimed to encapsulate two commonly used glucocorticoids with different potency and duration, hydrocortisone and dexamethasone, into poly(lactic-co-glycolic acid) (PLGA) nanoparticles with the goal to modulate inflammatory gene expression in a delivery-dependent manner. We evaluated their anti-inflammatory properties in two in vitro models varying the timing of treatment administration based on lipopolysaccharide M1-polarized macrophages, key effectors of the innate immune system. Our results demonstrated that, for both strategies, drug-loaded nanoparticles significantly reduced the expression of interleukin-6, a pro-inflammatory cytokine, compared to the free drugs. However, in one of the strategies, while free drugs induced upregulation of interleukin-10, a key anti-inflammatory cytokine, no such effect was observed with the nanoparticle-based formulations. Overall, these results demonstrate that PLGA nanoparticles enable sustained glucocorticoid delivery and modulate inflammatory gene expression in activated macrophages in a delivery- and timing-dependent manner, providing comparative insight into how glucocorticoid delivery via PLGA nanoparticles shapes inflammatory gene regulation depending on treatment timing and highlighting the importance of in vitro model design.</dc:description><dc:date>2026</dc:date><dc:source>http://zaguan.unizar.es/record/170172</dc:source><dc:doi>10.1039/d5nh00782h</dc:doi><dc:identifier>http://zaguan.unizar.es/record/170172</dc:identifier><dc:identifier>oai:zaguan.unizar.es:170172</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA/E15-20R</dc:relation><dc:relation>info:eu-repo/grantAgreement/EC/HORIZON EUROPE/101064735/EU/Tunning the force for remote magnetomechanical gating of Piezo1 channels/MAGPIEZ</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/CB16-01/00263</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/CEX2023-001286-S</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/PID2020-118485RB-I00</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/PID2022-141276OB-I00</dc:relation><dc:identifier.citation>Nanoscale Horizons (2026), [10 pp.]</dc:identifier.citation><dc:rights>by-nc</dc:rights><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/deed.es</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>